Mike M. Goldberg
Amministratore Delegato presso Macrophage Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Daniel B. Vickery | M | 60 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Michael Rice | M | 59 |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | 14 anni |
C. Lowell Parsons | M | 78 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 27 anni |
Alan Wayne Schoenbart | M | 65 | 10 anni | |
Mark I. Greene | M | 75 |
Macrophage Therapeutics, Inc.
Macrophage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Navidea Biopharmaceuticals, Inc., Macrophage Therapeutics, Inc. develops immune-oncology and anti-inflammatory therapeutics. The CEO of the American company is Mike M. Goldberg. | 3 anni |
Steven Slavsky | M | - |
CorNova, Inc.
CorNova, Inc. Medical SpecialtiesHealth Technology CorNova, Inc. develops medical devices. It product, FiberHalo SRM Stent Deployment Catheter, enables the physician to deploy a stent and measure in-stent lumen area during the angioplasty procedure. The company was founded by S. Eric Ryan in 2003 and is headquartered in Burlington, MA. | - |
Tim McInerney | M | 63 | 23 anni | |
Antoine Luc Maasdorp | M | 38 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Michael Weiser | M | 61 | 19 anni | |
Andrew McDonald | M | 50 |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Matthew Patrick Duffy | M | 61 |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Angela Qian | F | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Eric Goldstein | M | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Anne Chofflet | F | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Frank Gaul | M | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Larry Schlesinger | M | - |
Macrophage Therapeutics, Inc.
Macrophage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Navidea Biopharmaceuticals, Inc., Macrophage Therapeutics, Inc. develops immune-oncology and anti-inflammatory therapeutics. The CEO of the American company is Mike M. Goldberg. | - |
Thomas Rosol | M | - |
Macrophage Therapeutics, Inc.
Macrophage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Navidea Biopharmaceuticals, Inc., Macrophage Therapeutics, Inc. develops immune-oncology and anti-inflammatory therapeutics. The CEO of the American company is Mike M. Goldberg. | - |
Wael Jarjour | M | - |
Macrophage Therapeutics, Inc.
Macrophage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Navidea Biopharmaceuticals, Inc., Macrophage Therapeutics, Inc. develops immune-oncology and anti-inflammatory therapeutics. The CEO of the American company is Mike M. Goldberg. | - |
Carlo J. di Fonzo | M | - |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Ashley R. Robinson | F | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Michael Wood | M | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | 13 anni |
Michael Nordlicht | M | 36 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Robert L. Evans | M | - |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Meyer Feldberg | M | 82 |
Columbia Business School
| 40 anni |
David J. Waxman | M | - |
CorNova, Inc.
CorNova, Inc. Medical SpecialtiesHealth Technology CorNova, Inc. develops medical devices. It product, FiberHalo SRM Stent Deployment Catheter, enables the physician to deploy a stent and measure in-stent lumen area during the angioplasty procedure. The company was founded by S. Eric Ryan in 2003 and is headquartered in Burlington, MA. | - |
Robert Yedid | M | 66 |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | 10 anni |
Christopher M. Calabrese | M | - |
LifeSci Advisors LLC
LifeSci Advisors LLC Miscellaneous Commercial ServicesCommercial Services LifeSci Advisors LLC is an investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. Their services are designed to increase clients? visibility within the investment community and to educate investors about the opportunity. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Jed Andrew Latkin | M | 50 | 5 anni | |
Kimberly A. Burke | F | 50 | 6 anni | |
Solomon Steiner | M | 86 | 5 anni | |
Eric Rowinsky | M | 67 | 8 anni | |
Nachum Stein | M | 75 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 1 anni |
Lewis Bender | M | 65 | 14 anni | |
Joseph M. Leone | M | 70 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Ricardo J. Gonzalez | M | 53 | 2 anni | |
Jeffrey Sklar | M | 61 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Kenneth D. Pearsen | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 3 anni |
Alan Dunton | M | 70 | - | |
Shepard M. Goldberg | M | 69 | 3 anni | |
Gordon A. Troup | M | 70 | 8 anni | |
Steven C. Berger | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 anni |
Mark Pykett | M | 60 | 4 anni | |
Anton G. Gueth | M | 67 | 1 anni | |
Scott Wayne Hollander | M | 58 | 2 anni | |
Brent L. Larson | M | 61 | 20 anni | |
Thomas H. Bishop | M | 67 | 2 anni | |
Ebrahim Versi | M | 71 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Thomas Tulip | M | 71 | 4 anni | |
Christine H. Olimpio | F | - | 7 anni | |
Elazer Edelman | M | 67 | 1 anni | |
Tony Fiorino | M | 56 | 1 anni | |
Edward R. Teitel | M | 75 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 3 anni |
William Grieco | M | 70 | 3 anni | |
Claudine Bruck | M | 68 | 3 anni | |
Christopher P. Schnittker | M | 55 | 3 anni | |
Joseph Meyer | M | 36 | 6 anni | |
John Harkey | M | 63 | 14 anni | |
Mark Rachesky | M | 65 | 15 anni | |
Kenneth Londoner | M | 57 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 2 anni |
Richard Rosenblum | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 anni |
Peter Frank Drake | M | - | 4 anni | |
Vincent Enright | M | 80 | 6 anni | |
Brendan A. Ford | M | 66 | 6 anni | |
James Francis Smith | M | 74 | 3 anni | |
Tim O'Neill | M | - |
Columbia Business School
| 2 anni |
Xavier Rolet | M | 64 |
Columbia Business School
| 2 anni |
Mike P. Hermsen | M | 63 |
Columbia Business School
| 2 anni |
Tayfun Bayazit | M | 66 |
Columbia Business School
| 2 anni |
Laszlo Czirjak | M | - |
Columbia Business School
| 2 anni |
Beth Wahlig | F | - |
Columbia Business School
| 2 anni |
Walter D. Wick | M | - |
Columbia Business School
| 2 anni |
Elliot M. Maza | M | 68 | 3 anni | |
David Epstein | M | 62 |
Columbia Business School
| 2 anni |
Bernard Bollag | M | 63 |
Columbia Business School
| 2 anni |
Jonathan Leovy Stanley | M | - |
Columbia Business School
| 2 anni |
Stuart Aronson | M | 61 |
Columbia Business School
| 2 anni |
Joe Rosen | M | - |
Columbia Business School
| 2 anni |
Douglas Abrams | M | - |
Columbia Business School
| 2 anni |
Charles Thomas Bernhardt | M | 63 | - | |
Allan Baum | M | 68 |
Columbia Business School
| 2 anni |
Tony Pucillo | M | - |
Columbia Business School
| 2 anni |
Barbara E. Mohl | F | - | - | |
Jim Chaney | M | - |
Columbia Business School
| 2 anni |
Mary Guilfoile | F | 70 |
Columbia Business School
| 2 anni |
Robert I. Knibb | M | - |
Columbia Business School
| 2 anni |
Meera Khosla Mayer | F | - |
Columbia Business School
| 2 anni |
Leslie Chao | M | 67 |
Columbia Business School
| 2 anni |
Arthur Zuckerman | M | - |
Columbia Business School
| 2 anni |
Barbara Goodstein | F | 63 |
Columbia Business School
| 2 anni |
Michel Marc Patrick Brogard | M | 63 |
Columbia Business School
| 2 anni |
Randall Matthew Heck | M | 64 |
Columbia Business School
| 2 anni |
Laurent Gerard Ganem | M | 66 |
Columbia Business School
| 2 anni |
Mark Gallogly | M | 67 |
Columbia Business School
| 2 anni |
Robert J. Watkins | M | 81 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 3 anni |
Ted Karkus | M | 64 |
Columbia Business School
| 2 anni |
David Rose | M | - |
Columbia Business School
| 2 anni |
Nicos Katsoulis | M | 64 |
Columbia Business School
| 2 anni |
Andrew Savin | M | - |
Columbia Business School
| 2 anni |
Jerry Chafkin | M | 65 |
Columbia Business School
| 2 anni |
Thomas Tryforos | M | 65 |
Columbia Business School
| 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mike M. Goldberg
- Contatti personali